WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
HMB is believed to reduce muscle protein breakdown in humans by inhibiting the 19S and 20S subunits of the ubiquitin–proteasome system in skeletal muscle and by inhibiting apoptosis of skeletal muscle nuclei via unidentified mechanisms. Based upon animal studies, HMB appears to be metabolized within skeletal muscle into cholesterol, which may then be incorporated into the muscle cell membrane, thereby enhancing membrane integrity and function. The effects of HMB on muscle protein metabolism may help stabilize muscle cell structure. One review suggested that the observed HMB-induced reduction in the plasma concentration of muscle damage biomarkers (i.e., muscle enzymes such as creatine kinase and lactate dehydrogenase) in humans following intense exercise may be due to a cholesterol-mediated improvement in muscle cell membrane function. HMB has been shown to stimulate the proliferation, differentiation, and fusion of human myosatellite cells in vitro, which potentially increases the regenerative capacity of skeletal muscle, by increasing the protein expression of certain myogenic regulatory factors (e.g., myoD and myogenin) and gene transcription factors (e.g., MEF2). HMB-induced human myosatellite cell proliferation in vitro is mediated through the phosphorylation of the mitogen-activated protein kinases ERK1 and ERK2. HMB-induced human myosatellite differentiation and accelerated fusion of myosatellite cells into muscle tissue in vitro is mediated through the phosphorylation of Akt, a serine/threonine-specific protein kinase.
Omeprazole was the first PPI on the market, in 1988. It is a 1:1 racemate drug with a backbone structure of timoprazole, but substituted with two methoxy and two methyl groups. One of the methoxy group is at position 6 of the benzimidazole and the other at position 4 of the pyridine and the methyl groups are at position 3 and 5 of the pyridine. Omeprazole is available as enteric-coated tablets, capsules, chewable tablets, powder for oral suspensions and powder for intravenous injection.
The rotation of plane polarized light by chiral substances was first observed by Jean-Baptiste Biot in 1812, and gained considerable importance in the sugar industry, analytical chemistry, and pharmaceuticals. Louis Pasteur deduced in 1848 that this phenomenon has a molecular basis. The term chirality itself was coined by Lord Kelvin in 1894. Individual enantiomers or diastereomers of a compound were formerly called optical isomers due to their distinct optical properties. At one time, chirality was thought to be restricted to organic chemistry, but this misconception was overthrown by the resolution of a purely inorganic compound, a cobalt complex called hexol, by Alfred Werner in 1911. In the early 1970s, various groups established that the human olfactory organ is capable of distinguishing chiral compounds.
The plan was that Johannesburg would revolt and seize the Boer armoury in Pretoria. Jameson and his force would dash across the border to Johannesburg to "restore order" and with control of Johannesburg would control the gold fields. However, while Jameson waited for the insurrection to begin, differences arose within the Reform Committee and between Johannesburg Uitlander reformers regarding the form of government to be adopted after the coup. At a point, certain reformers contacted Jameson to inform him of the difficulties and advised him to stand down. Jameson, with 600 restless men and other pressures, became frustrated by the delays and, believing that he could spur the reluctant Johannesburg reformers to act, decided to go ahead. He sent a telegram on 28 December 1895 to Rhodes warning him of his intentions – "Unless I hear definitely to the contrary, shall leave to-morrow evening" – and on the very next day sent a further message, "Shall leave to-night for the Transvaal". However, the transmission of the first telegram was delayed, so that both arrived at the same time on the morning of 29 December, and by then Jameson's men had cut the telegraph wires and there was no way of recalling him. On 29 December 1895, Jameson's armed column crossed into the Transvaal and headed for Johannesburg. They hoped that this would be a three-day dash to Johannesburg before the Boer commandos could mobilise, and would trigger an uprising by the Uitlanders.
Sources: en.wikipedia.org
=== Size === Bottles tend to come in standard sizes, often 4 US fluid ounces (120 ml) and 8 US fluid ounces (240 ml). Smaller bottles may be lighter and easier to hold and are often used with younger, smaller infants. There are concerns that larger bottles may lead to over-feeding, since parents are likely to encourage a baby to "finish" a bottle during a feeding. The height-to-width ratio of bottles is high (relative to adult cups) because it is needed to ensure the contents flood the teat when used at normal angles; otherwise the baby will drink air. However, if the bottle is too tall, it easily tips. There are asymmetric bottles that ensure the contents flood the teat if the bottle is held at a certain direction.
=== Solvents === CV can be conducted using a variety of solutions. Solvent choice for cyclic voltammetry takes into account several requirements. The solvent must dissolve the analyte and high concentrations of the supporting electrolyte. It must also be stable in the potential window of the experiment with respect to the working electrode. It must not react with either the analyte or the supporting electrolyte. It must be pure to prevent interference.
C6H12O6 + 2 ADP + 2 Pi → 2 CH3CH(OH)COOH + 2 ATP + 2 H2O Anaerobic respiration is respiration in the absence of O2. Prokaryotes can utilize a variety of electron acceptors. These include nitrate, sulfate, and carbon dioxide. In anaerobic organisms and prokaryotes, different pathways result in ATP. ATP is produced in the chloroplasts of green plants in a process similar to oxidative phosphorylation, called photophosphorylation.
"A Fighter From the Ground Up." Popular Science, July 1943, one of earliest detailed articles on P-51A Archived 23 October 2013 at the Wayback Machine "Wild Horses of the Sky," Popular Mechanics, November 1943 Joe Baugher, North American P-51 Mustang Archived 23 July 2011 at the Wayback Machine Camouflage and Markings of P-51 Mustang Parts 1–4 USAAF plus Allison engine versions RAF and Commonwealth Archived 1 March 2012 at the Wayback Machine Allison-powered Mustang performance test reports; 1940, 1942, 1943, 1944 Archived 22 December 2008 at the Wayback Machine P-51B Mustang performance test report, May 1943 Archived 9 January 2008 at the Wayback Machine P-51 combat reports Archived 23 December 2007 at the Wayback Machine NACA-WR-L-566 "Flying qualities and stalling characteristics of North American XP-51 airplane", April 1943. (PDF) North American P-51 profile, photos and technical details for each mk "Flight Characteristics of the North American P-51 Mustang: How to Fly the P-51 Mustang" on YouTube "Mustang Squadron" a 1942 Flight article "Army Co-Op Mustang" a 1942 Flight article "Unobtrusive Cleverness" a 1942 Flight article "Long Range Mustang" a 1944 Flight article P-51 in Flight Over California (1942) Flight manual Mustang P-51A Archived 15 May 2024 at the Wayback Machine – The Museum of Flight Digital Collections Pilot training manual for the Mustang P-51 Archived 8 October 2024 at the Wayback Machine – The Museum of Flight Digital Collections
There are two kinds of targeted drug delivery: active targeted drug delivery, such as some antibody medications, and passive targeted drug delivery, such as the enhanced permeability and retention effect (EPR-effect).
Sources: en.wikipedia.org
== Contamination and response in 2009–2010 == On 2 December 2009, China detained three employees of Shaanxi Jinqiao Dairy Company in northwest China suspected of selling 5.25 tons of melamine-laced powdered milk to Nanning Yueqian Food Additive Company, in Guangxi. On 30 December 2009, Xinhua reported continuing problems: powder and flavouring products sold by another company involved in the original scandal–the Shanghai Panda Dairy Company–were found to contain illegal levels of melamine; the dairy was closed and three of its executives arrested. On 25 January 2010, it was reported that three food companies from Hebei, Liaoning and Shandong provinces had produced melamine tainted products in March and April 2009 and that the three companies were banned from selling products in Guizhou. On 10 February 2010 China's state council announced a food safety commission, consisting of three vice premiers and a dozen minister-level officials, to address the nation's food regulatory problems. The group aims to improve government coordination and enforcement and to solve systemic food safety problems. As part of its ongoing effort to find and destroy any melamine-tainted milk remaining on the market, the Chinese government announced that it was recalling 170 tons of powdered milk laced with the industrial chemical which was supposed to have been destroyed or buried in 2008 but has recently found to have been repackaged and placed back into the marketplace.
Several new methods for DNA sequencing were developed in the mid to late 1990s and were implemented in commercial DNA sequencers by 2000. Together these were called the "next-generation" or "second-generation" sequencing (NGS) methods, in order to distinguish them from the earlier methods, including Sanger sequencing. In contrast to the first generation of sequencing, NGS technology is typically characterized by being highly scalable, allowing the entire genome to be sequenced at once. Usually, this is accomplished by fragmenting the genome into small pieces, randomly sampling for a fragment, and sequencing it using one of a variety of technologies, such as those described below. An entire genome is possible because multiple fragments are sequenced at once (giving it the name "massively parallel" sequencing) in an automated process. NGS technology has tremendously empowered researchers to look for insights into health, anthropologists to investigate human origins, and is catalyzing the "Personalized Medicine" movement. However, it has also opened the door to more room for error. There are many software tools to carry out the computational analysis of NGS data, often compiled at online platforms such as CSI NGS Portal, each with its own algorithm. Even the parameters within one software package can change the outcome of the analysis. In addition, the large quantities of data produced by DNA sequencing have also required development of new methods and programs for sequence analysis.
The inhibition of PFK1 by ATP is unusual since ATP is also a substrate in the reaction catalyzed by PFK1. The active form of PFK1 enzyme is a tetramer that exists in two conformations, only one of which binds the second substrate fructose-6-phosphate (F6P). The PFK1 enzyme has two binding sites for ATP – the active site is accessible in either protein conformation, but ATP binding to the inhibitor site stabilizes the conformation that binds F6P poorly. A number of other small molecules can compensate for the ATP-induced shift in equilibrium conformation and reactivate PFK1, including cyclic AMP, ammonium ions, inorganic phosphate, fructose 1,6-bisphosphate and fructose 2,6-bisphosphate.
== Capillary electrochromatography == Capillary electrochromatography (CEC) is an electrochromatography technique in which the liquid mobile phase is driven through a capillary containing the chromatographic stationary phase by electroosmosis. It is a combination of high-performance liquid chromatography and capillary electrophoresis. The capillaries is packed with HPLC stationary phase and a high voltage is applied to achieve separation is achieved by electrophoretic migration of the analyte and differential partitioning in the stationary phase.
== History == LFTs derive from paper chromatography, which was developed in 1943 by Martin and Synge, and elaborated in 1944 by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945. The ELISA technology was developed in 1971. A set of LFT patents, including the litigated US 6,485,982 described below, were filed by Armkel LLC starting in 1988. The first commercially available lateral flow device was Unipath's Clearblue One Step in 1988. This product combined Paired Monoclonal Antibody technology (patented in 1980 by Unipath's Prof. Philip Porter and colleagues including Paul Davis and Keith May) and the original Clearblue product launched in June 1985.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.